TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 3nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 4nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 9nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 25nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: >300nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 790nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair
Affinity DataKd: 1.20E+4nMAssay Description:Binding affinity to first site on human serum albumin by SPRMore data for this Ligand-Target Pair